《活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版)》的免疫辅助治疗解读

doi:10.19982/j.issn.1000-6621.20220066

摘要/Abstract

摘要：

结核病的发生、发展及转归与患者的抗结核免疫功能密切相关。结核病患者常常存在抗结核免疫功能的异常,对结核病患者应用免疫制剂进行免疫干预,可提高治愈率、降低复发率,但对活动性结核病患者免疫干预的指征、免疫制剂的选择尚未达成一致意见。发表于《中国防痨杂志》2022年第1期的《活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版)》就抗结核免疫辅助治疗提出了具体建议并达成共识。本文主要对共识中结核病患者免疫异常因素、活动性结核病患者免疫辅助治疗概念、应用免疫制剂进行免疫干预的临床应用及存在问题和建议等进一步解读,以供我国结核病临床工作者借鉴和参考。

关键词: 结核, 免疫疗法, 总结性报告(主题), 评论

Abstract:

The occurrence, development and prognosis of tuberculosis (TB) are closely related to anti-TB immune function. TB patients often have anti-TB immune function abnormalities, the immune intervention using immune agents can improve the cure rate and reduced the recurrence rate. However, there is no consensus on the immune intervention and selection of immune agents for active TB. Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition) published in No.1 of 2022 in Chinese Journal of Antituberculosis proposed specific suggestions and reached consensus on anti-TB immunotherapy. The factors of immune abnormality in TB patients, the concept of immunoadjuvant therapy for active TB, the clinical application of the immune intervention were further interpreted in this paper, to provide the reference of TB clinical workers in China.

Key words: Tuberculosis, Immunotherapy, Consensus development conferences as topic, Comment

中图分类号:

R730.51
R52

安慧茹, 吴雪琼. 《活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版)》的免疫辅助治疗解读[J]. 中国防痨杂志, 2022, 44(6): 539-543. doi: 10.19982/j.issn.1000-6621.20220066

AN Hui-ru, WU Xue-qiong. Interpretation of immunoadjuvant therapy in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition)[J]. Chinese Journal of Antituberculosis, 2022, 44(6): 539-543. doi: 10.19982/j.issn.1000-6621.20220066

参考文献 29

[1]	Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis Infections. Microbiol Spectr, 2019, 7(4): 10.1128/microbiolspec.GPP3-0022-2018. doi: 10.1128/microbiolspec.GPP3-0022-2018. doi: 10.1128/microbiolspec.GPP3-0022-2018
[2]	Roy S, Schmeier S, Kaczkowski B, et al. Transcriptional landscape of Mycobacterium tuberculosis infection in macrophages. Sci Rep, 2018, 8(1): 6758. doi: 10.1038/s41598-018-24509-6. doi: 10.1038/s41598-018-24509-6 URL
[3]	中国人民解放军总医院第八医学中心全军结核病研究所/全军结核病防治重点实验室/结核病诊疗新技术北京市重点实验室, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础和临床学部. 活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版). 中国防痨杂志, 2022, 44(1): 9-27. doi: 10.19982/j.issn.1000-6621.20210680. doi: 10.19982/j.issn.1000-6621.20210680
[4]	Sampath P, Moideen K, Ranganathan UD, et al. Monocyte Subsets: Phenotypes and Function in Tuberculosis Infection. Front Immunol, 2018, 9:1726. doi: 10.3389/fimmu.2018.01726. doi: 10.3389/fimmu.2018.01726 URL
[5]	Shi L, Jiang Q, Bushkin Y, et al. Biphasic Dynamics of Macrophage Immunometabolism during Mycobacterium tuberculosis Infection. mBio, 2019, 10(2): e02550-18. doi: 10.1128/mBio.02550-18. doi: 10.1128/mBio.02550-18
[6]	Garand M, Goodier M, Owolabi O, et al. Functional and Phenotypic Changes of Natural Killer Cells in Whole Blood during Mycobacterium tuberculosis Infection and Disease. Front Immunol, 2018, 9:257. doi: 10.3389/fimmu.2018.00257. doi: 10.3389/fimmu.2018.00257 URL
[7]	Tully G, Kortsik C, Höhn H, et al. Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection. J Immunol, 2005, 174(4): 2174-2184. doi: 10.4049/jimmunol.174.4.2174. doi: 10.4049/jimmunol.174.4.2174 URL
[8]	Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol, 2009, 27:393-422. doi: 10.1146/annurev.immunol.021908.132703. doi: 10.1146/annurev.immunol.021908.132703 URL
[9]	Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol, 2011, 4(3): 288-293. doi: 10.1038/mi.2011.10. doi: 10.1038/mi.2011.10 pmid: 21451503
[10]	Morgan J, Muskat K, Tippalagama R, et al. Classical CD4 T cells as the cornerstone of antimycobacterial immunity. Immunol Rev, 2021, 301(1): 10-29. doi: 10.1111/imr.12963. doi: 10.1111/imr.12963 URL
[11]	Harris J, De Haro SA, Master SS, et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity, 2007, 27(3): 505-517. doi: 10.1016/j.immuni.2007.07.022. doi: 10.1016/j.immuni.2007.07.022 pmid: 17892853
[12]	Schurz H, Daya M, Möller M et al. TLR1, 2, 4, 6 and 9 Variants Associated with Tuberculosis Susceptibility: A Systematic Review and Meta-Analysis. PLoS One, 2015, 10(10):e0139711. doi: 10.1371/journal.pone.0139711. doi: 10.1371/journal.pone.0139711
[13]	Sadki K, Lamsyah H, Rueda B, et al. Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population. J Genet Genomics, 2010, 37(4): 257-264. doi: 10.1016/s1673-8527(09)60044-8. doi: 10.1016/s1673-8527(09)60044-8 URL
[14]	Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe, 2008, 3(6): 399-407. doi: 10.1016/j.chom.2008.05.006. doi: 10.1016/j.chom.2008.05.006 pmid: 18541216
[15]	Liu C, He T, Rong Y, et al. Association of Mannose-binding Lectin Polymorphisms with Tuberculosis Susceptibility among Chinese. Sci Rep, 2016, 6:36488. doi: 10.1038/srep36488. doi: 10.1038/srep36488 URL
[16]	Boisson-Dupuis S. The monogenic basis of human tuberculosis. Hum Genet, 2020, 139(6/7): 1001-1009. doi: 10.1007/s00439-020-02126-6. doi: 10.1007/s00439-020-02126-6 URL
[17]	Ogishi M, Yang R, Aytekin C, et al. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nat Med, 2021, 27(9): 1646-1654. doi: 10.1038/s41591-021-01388-5. doi: 10.1038/s41591-021-01388-5 URL
[18]	Pires D, Marques J, Pombo JP, et al. Role of Cathepsins in Mycobacterium tuberculosis Survival in Human Macrophages. Sci Rep, 2016, 6:32247. doi: 10.1038/srep32247. doi: 10.1038/srep32247 URL
[19]	Koul A, Herget T, Klebl B, et al. Interplay between mycobacteria and host signalling pathways. Nat Rev Microbiol, 2004, 2(3): 189-202. doi: 10.1038/nrmicro840. doi: 10.1038/nrmicro840 URL
[20]	Li F, Feng L, Jin C, et al. LpqT improves mycobacteria survival in macrophages by inhibiting TLR2 mediated inflammatory cytokine expression and cell apoptosis. Tuberculosis (Edinb), 2018, 111:57-66. doi: 10.1016/j.tube.2018.05.007. doi: 10.1016/j.tube.2018.05.007 URL
[21]	尚晓倩, 赵慧, 马秀敏慧,等. microRNA与结核分枝杆菌感染的致病机制研究进展. 中华医院感染学杂志, 2019, 29(3): 477-480. doi: 10.11816/cn.ni.2019-174265. doi: 10.11816/cn.ni.2019-174265
[22]	张益源, 伊正君, 付玉荣. microRNA在结核分枝杆菌抗细胞自噬作用中的研究进展. 生物化学与生物物理进展, 2019, 46(1): 43-50. doi: 10.16476/j.pibb.2018.0133. doi: 10.16476/j.pibb.2018.0133
[23]	Portal-Celhay C, Tufariello JM, Srivastava S, et al. Mycobacterium tuberculosis EsxH inhibits ESCRT-dependent CD4⁺ T-cell activation. Nat Microbiol, 2016, 2:16232. doi: 10.1038/nmicrobiol.2016.232. doi: 10.1038/nmicrobiol.2016.232 pmid: 27918526
[24]	Schildberg FA, Klein SR, Freeman GJ, et al. Coinhibitory Pathways in the B7-CD 28 Ligand-Receptor Family. Immunity, 2016, 44(5): 955-972. doi: 10.1016/j.immuni.2016.05.002. doi: 10.1016/j.immuni.2016.05.002 pmid: 27192563
[25]	Wang L, Wu J, Li J, et al. Host-mediated ubiquitination of a mycobacterial protein suppresses immunity. Nature, 2020, 577(7792): 682-688. doi: 10.1038/s41586-019-1915-7. doi: 10.1038/s41586-019-1915-7 URL
[26]	Roy E, Lowrie DB, Jolles SR. Current strategies in TB immunotherapy. Curr Mol Med, 2007, 7(4): 373-386. doi: 10.2174/156652407780831557. doi: 10.2174/156652407780831557 URL
[27]	Periyasamy KM, Ranganathan UD, Tripathy SP, et al. Vitamin D-A host directed autophagy mediated therapy for tuberculosis. Mol Immunol, 2020, 127:238-244. doi: 10.1016/j.molimm.2020.08.007. doi: 10.1016/j.molimm.2020.08.007 pmid: 33039674
[28]	Byeon S, Cho JH, Jung HA, et al. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. Cancer Med, 2020, 9(7): 2352-2362. doi: 10.1002/cam4.2868. doi: 10.1002/cam4.2868 URL
[29]	付亮, 梁娟, 张国良等. γδT细胞在结核病免疫治疗的研究及其应用前景. 中国防痨杂志, 2019, 41(6): 695-699. doi: 10.3969/j.issn.1000-6621.2019.06.019. doi: 10.3969/j.issn.1000-6621.2019.06.019